Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

The average body surface area of adult cancer patients in the UK: a multicentre retrospective study.

Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P.

PLoS One. 2010 Jan 28;5(1):e8933. doi: 10.1371/journal.pone.0008933.

2.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

3.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

4.

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L.

Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440. Review.

5.
6.

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E.

Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470. Review.

7.

Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.

Facey K, Bradbury I, Laking G, Payne E.

Health Technol Assess. 2007 Oct;11(44):iii-iv, xi-267. Review.

8.

Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.

Ratnavelu ND, Brown AP, Mallett S, Scholten RJ, Patel A, Founta C, Galaal K, Cross P, Naik R.

Cochrane Database Syst Rev. 2016 Mar 1;3:CD010360. doi: 10.1002/14651858.CD010360.pub2. Review.

PMID:
26930463
9.

Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.

[No authors listed]

Drugs R D. 2005;6(3):178-85. Review.

PMID:
15869322
10.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
11.

ABI 007.

[No authors listed]

Drugs R D. 2004;5(3):155-9. Review.

PMID:
15139776
12.

High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors.

McGuire WP.

Curr Probl Cancer. 1998 May-Jun;22(3):135-77. Review.

PMID:
9659570
13.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Dickinson HO.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004706. doi: 10.1002/14651858.CD004706.pub2. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD004706.

PMID:
19160239
14.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Dickinson HO.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004706. doi: 10.1002/14651858.CD004706.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;3:CD004706.

PMID:
19588360
15.

The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.

Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafström L, Haglund U, Högberg T, Janunger KG, Jönsson PE, Karlsson G, Kimby E, Lamnevik G, Nilsson S, Permert J, Ragnhammar P, Sörenson S, Nygren P.

Acta Oncol. 2001;40(2-3):135-54. Review.

PMID:
11441927
16.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
17.

Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.

Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A.

Health Technol Assess. 2007 Oct;11(40):1-144. Review.

18.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Winter-Roach BA, Kitchener HC, Lawrie TA.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD004706. doi: 10.1002/14651858.CD004706.pub4. Review. Update in: Cochrane Database Syst Rev. 2015;(12):CD004706.

19.

Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.

Skoetz N, Bohlius J, Engert A, Monsef I, Blank O, Vehreschild JJ.

Cochrane Database Syst Rev. 2015 Dec 21;(12):CD007107. doi: 10.1002/14651858.CD007107.pub3. Review.

20.

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.

Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Review. Erratum in: Health Technol Assess. 2015 May;17(31):281-2.

Supplemental Content

Support Center